Publisher Summary Nucleic acid pharmaceuticals are of increasing interest to the health
care community because of their almost unlimited potential in the treatment of diseases such
as cancer, genetic and degenerative disorders, viral infection, and the molecular pathologic
sequelae of trauma or ischemia. Modified antisense oligodeoxynucleotides
(oligonucleotides; ODNs) offer the potential to block the expression of specific genes within
cells. Such strategies have antiproliferative activity in rapidly dividing cells when directed at …